Alpha Cognition Inc. (ACOG)
NASDAQ: ACOG · Real-Time Price · USD
6.94
+0.29 (4.36%)
At close: Apr 17, 2026, 4:00 PM EDT
7.08
+0.14 (2.02%)
After-hours: Apr 17, 2026, 6:05 PM EDT
Alpha Cognition Revenue
In the year 2025, Alpha Cognition had annual revenue of $10.22M. Alpha Cognition had revenue of $2.79M in the quarter ending December 31, 2025.
Revenue (ttm)
$10.22M
Revenue Growth
n/a
P/S Ratio
14.79
Revenue / Employee
n/a
Employees
n/a
Market Cap
151.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.22M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Spero Therapeutics | 66.80M |
| Innate Pharma | 10.57M |
| Fate Therapeutics | 6.65M |
| Oramed Pharmaceuticals | 2.00M |
| Kazia Therapeutics | 1.27M |
| Molecular Partners AG | 856.30K |
| Genelux | 8.00K |
ACOG News
- 3 days ago - Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury - Business Wire
- 18 days ago - Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425 - Newsfile Corp
- 24 days ago - Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update - Business Wire
- 5 weeks ago - Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026 - Business Wire
- 5 weeks ago - Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences - Business Wire
- 7 weeks ago - Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study - Business Wire
- 2 months ago - Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens - Business Wire